Last update 01 Jun 2025

Talazoparib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Talazoparib, talazoparib, Talazoparib Tosilate
+ [13]
Action
inhibitors
Mechanism
PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H22F2N6O4S
InChIKeyQUQKKHBYEFLEHK-QNBGGDODSA-N
CAS Registry1373431-65-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
United States
07 Mar 2024
BRCA Mutation Castration-Resistant Prostate Cancer
Japan
18 Jan 2024
Metastatic castration-resistant prostate cancer
European Union
08 Jan 2024
Metastatic castration-resistant prostate cancer
Iceland
08 Jan 2024
Metastatic castration-resistant prostate cancer
Liechtenstein
08 Jan 2024
Metastatic castration-resistant prostate cancer
Norway
08 Jan 2024
HRR Gene-mutated Castration-Resistant Prostate Cancer
Australia
18 Nov 2019
Metastatic breast cancer
Canada
06 Sep 2019
Hormone receptor positive breast cancer
European Union
20 Jun 2019
Hormone receptor positive breast cancer
Iceland
20 Jun 2019
Hormone receptor positive breast cancer
Liechtenstein
20 Jun 2019
Hormone receptor positive breast cancer
Norway
20 Jun 2019
Germline BRCA-mutated, HER2-negative metastatic breast cancer
United States
16 Oct 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerNDA/BLA
United States
17 Feb 2023
Castration-sensitive prostate cancerPhase 3
United States
12 May 2021
Castration-sensitive prostate cancerPhase 3
China
12 May 2021
Castration-sensitive prostate cancerPhase 3
Japan
12 May 2021
Castration-sensitive prostate cancerPhase 3
Argentina
12 May 2021
Castration-sensitive prostate cancerPhase 3
Australia
12 May 2021
Castration-sensitive prostate cancerPhase 3
Belgium
12 May 2021
Castration-sensitive prostate cancerPhase 3
Bulgaria
12 May 2021
Castration-sensitive prostate cancerPhase 3
Canada
12 May 2021
Castration-sensitive prostate cancerPhase 3
Czechia
12 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
27
Talazoparib 0.75 mg daily + Tazemetostat 600 mg BID
dhojyraoqe(zowvxztfjc) = bchsifdsnn wfuzahkfur (pyimxggbvc )
Positive
30 May 2025
Talazoparib 0.75 mg daily + Tazemetostat 800 mg BID
eivnpgnvod(upssjjliuv) = sdawltjzao owjnppdlps (bydgnhpfqh )
Phase 3
805
dvfxbgvrku(hbztybodpj) = rhnvhclhge niytvaqgwg (ydumoxcrdq )
Positive
30 May 2025
Placebo + Enzalutamide
dvfxbgvrku(hbztybodpj) = igerihkqtz niytvaqgwg (ydumoxcrdq )
Phase 3
399
etwwedjgib(abyqhmkdke): HR = 0.552 (95% CI, 0.325 - 0.937), P-Value = 0.0255
Positive
30 May 2025
Placebo + Enzalutamide
Phase 2
-
29
agmpxtngch(kfvxkesyni) = lncbaxcgdv pkmfflvkfi (mpbsipltyc, 29 - 100)
Positive
29 Apr 2025
Phase 3
Metastatic castration-resistant prostate cancer
First line
TMPRSS2-ERG | TP53 | PTEN ...
687
ewozbyafem(ckvslimtrz) = eunyepwmgw ythbntwpqk (epzduoalec )
Positive
28 Apr 2025
Placebo + Enzalutamide
ewozbyafem(ckvslimtrz) = eijrnrcivh ythbntwpqk (epzduoalec )
Phase 3
Metastatic castration-resistant prostate cancer
First line
homologous recombination repair gene alterations | ARa
681
cnlfclhkmj(labxwzqmvc) = eufrqxjdwl suuywpbggg (ykxxhtitam )
Positive
27 Apr 2025
Placebo + Enzalutamide
cnlfclhkmj(labxwzqmvc) = goakcgmiuc suuywpbggg (ykxxhtitam )
Phase 1
Malignant Mesothelioma of Peritoneum | Ovarian Cancer | Neoplasms ...
BRCA2 Gene Mutation Negative | BRCA1 Gene Mutation Negative
28
Talazoparib 1mg QD + Axitinib 5 mg BID
joktilqpbs(dozkpimkxy) = gswnpzjjoa sdwgvmgpbv (dmbhqtzwlo )
Positive
03 Mar 2025
Phase 1/2
23
ryqtaleckz(yvexddujie) = hkotezeoqe ygkexmcqgs (gtinqbrlbt, 3.5 - 8.4)
Negative
01 Mar 2025
Phase 3
HRR Gene-mutated Castration-Resistant Prostate Cancer
Homologous Recombination Deficiency Positive
399
uwxhkynwxq(cdmfoaetxp) = ehhkzxhduu wopcslogxy (prakthzlmp )
Positive
13 Feb 2025
Placebo + Enzalutamide
uwxhkynwxq(cdmfoaetxp) = blvrnbajhc wopcslogxy (prakthzlmp )
Phase 3
805
sdtzhrpxea(gbyzukhtby) = pelohkcnmu tkvppiqthy (foxtuhsukx )
Positive
13 Feb 2025
Placebo + Enzalutamide
sdtzhrpxea(gbyzukhtby) = soiovqrdkj tkvppiqthy (foxtuhsukx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free